3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia

Ruth Condray, George G. Dougherty, Matcheri S. Keshavan, Ravinder D. Reddy, Gretchen L. Haas, Debra M. Montrose, Wayne R. Matson, Joseph Patrick McEvoy, Rima Kaddurah-Daouk, Jeffrey K. Yao

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

One branch of the tryptophan catabolic cascade is the kynurenine pathway, which produces neurotoxic [3-hydroxykynurenine (3-OHKY), quinolinic acid] and neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts as a competitive antagonist at the glycine site of N-methyl-d-asparate receptors at high concentrations and as a non-competitive antagonist on the α7- nicotinic acetylcholine receptor at low concentrations. Kynurenine compounds also influence cognitive functions known to be disrupted in schizophrenia. Alterations in tryptophan metabolism are therefore of potential significance for the pathophysiology of this disorder. In this paper, tryptophan metabolites were measured from plasma using high-pressure liquid chromatography coupled with electrochemical coulometric array detection, and relationships were tested between these metabolic signatures and clinical symptoms for 25 first-episode neuroleptic-naive schizophrenia patients. Blood samples were collected and clinical and neurological symptoms were rated at baseline and again at 4 wk following initiation of treatment. Level of 3-OHKY and total clinical symptom scores were correlated when patients were unmedicated and neuroleptic-naive, and this relationship differed significantly from the correlation observed for patients 4 wk after beginning treatment. Baseline psychosis symptoms were predicted only by neurological symptoms. Moreover, baseline 3-OHKY predicted clinical change at 4 wk, with the lowest concentrations of 3-OHKY being associated with the greatest improvement in symptoms. Taken together, our findings suggest a neurotoxic product of tryptophan metabolism, 3-OHKY, predicts severity of clinical symptoms during the early phase of illness and before exposure to antipsychotic drugs. Baseline level of 3-OHKY may also predict the degree of clinical improvement following brief treatment with antipsychotics.

Original languageEnglish (US)
Pages (from-to)756-767
Number of pages12
JournalInternational Journal of Neuropsychopharmacology
Volume14
Issue number6
DOIs
StatePublished - Jul 1 2011

Fingerprint

Tryptophan
Antipsychotic Agents
Schizophrenia
Kynurenic Acid
Kynurenine
Sarcosine
Quinolinic Acid
Nicotinic Receptors
Psychotic Disorders
Cognition
Therapeutics
High Pressure Liquid Chromatography
3-hydroxykynurenine

Keywords

  • 3-hydroxykynurenine
  • Cognition
  • first-episode psychosis
  • neuroleptic-naive
  • neurological symptoms
  • schizophrenia
  • tryptophan

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Condray, R., Dougherty, G. G., Keshavan, M. S., Reddy, R. D., Haas, G. L., Montrose, D. M., ... Yao, J. K. (2011). 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. International Journal of Neuropsychopharmacology, 14(6), 756-767. https://doi.org/10.1017/S1461145710001689

3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. / Condray, Ruth; Dougherty, George G.; Keshavan, Matcheri S.; Reddy, Ravinder D.; Haas, Gretchen L.; Montrose, Debra M.; Matson, Wayne R.; McEvoy, Joseph Patrick; Kaddurah-Daouk, Rima; Yao, Jeffrey K.

In: International Journal of Neuropsychopharmacology, Vol. 14, No. 6, 01.07.2011, p. 756-767.

Research output: Contribution to journalArticle

Condray, R, Dougherty, GG, Keshavan, MS, Reddy, RD, Haas, GL, Montrose, DM, Matson, WR, McEvoy, JP, Kaddurah-Daouk, R & Yao, JK 2011, '3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia', International Journal of Neuropsychopharmacology, vol. 14, no. 6, pp. 756-767. https://doi.org/10.1017/S1461145710001689
Condray, Ruth ; Dougherty, George G. ; Keshavan, Matcheri S. ; Reddy, Ravinder D. ; Haas, Gretchen L. ; Montrose, Debra M. ; Matson, Wayne R. ; McEvoy, Joseph Patrick ; Kaddurah-Daouk, Rima ; Yao, Jeffrey K. / 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. In: International Journal of Neuropsychopharmacology. 2011 ; Vol. 14, No. 6. pp. 756-767.
@article{21de90b3849c4b72aa7b09af142017ec,
title = "3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia",
abstract = "One branch of the tryptophan catabolic cascade is the kynurenine pathway, which produces neurotoxic [3-hydroxykynurenine (3-OHKY), quinolinic acid] and neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts as a competitive antagonist at the glycine site of N-methyl-d-asparate receptors at high concentrations and as a non-competitive antagonist on the α7- nicotinic acetylcholine receptor at low concentrations. Kynurenine compounds also influence cognitive functions known to be disrupted in schizophrenia. Alterations in tryptophan metabolism are therefore of potential significance for the pathophysiology of this disorder. In this paper, tryptophan metabolites were measured from plasma using high-pressure liquid chromatography coupled with electrochemical coulometric array detection, and relationships were tested between these metabolic signatures and clinical symptoms for 25 first-episode neuroleptic-naive schizophrenia patients. Blood samples were collected and clinical and neurological symptoms were rated at baseline and again at 4 wk following initiation of treatment. Level of 3-OHKY and total clinical symptom scores were correlated when patients were unmedicated and neuroleptic-naive, and this relationship differed significantly from the correlation observed for patients 4 wk after beginning treatment. Baseline psychosis symptoms were predicted only by neurological symptoms. Moreover, baseline 3-OHKY predicted clinical change at 4 wk, with the lowest concentrations of 3-OHKY being associated with the greatest improvement in symptoms. Taken together, our findings suggest a neurotoxic product of tryptophan metabolism, 3-OHKY, predicts severity of clinical symptoms during the early phase of illness and before exposure to antipsychotic drugs. Baseline level of 3-OHKY may also predict the degree of clinical improvement following brief treatment with antipsychotics.",
keywords = "3-hydroxykynurenine, Cognition, first-episode psychosis, neuroleptic-naive, neurological symptoms, schizophrenia, tryptophan",
author = "Ruth Condray and Dougherty, {George G.} and Keshavan, {Matcheri S.} and Reddy, {Ravinder D.} and Haas, {Gretchen L.} and Montrose, {Debra M.} and Matson, {Wayne R.} and McEvoy, {Joseph Patrick} and Rima Kaddurah-Daouk and Yao, {Jeffrey K.}",
year = "2011",
month = "7",
day = "1",
doi = "10.1017/S1461145710001689",
language = "English (US)",
volume = "14",
pages = "756--767",
journal = "International Journal of Neuropsychopharmacology",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "6",

}

TY - JOUR

T1 - 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia

AU - Condray, Ruth

AU - Dougherty, George G.

AU - Keshavan, Matcheri S.

AU - Reddy, Ravinder D.

AU - Haas, Gretchen L.

AU - Montrose, Debra M.

AU - Matson, Wayne R.

AU - McEvoy, Joseph Patrick

AU - Kaddurah-Daouk, Rima

AU - Yao, Jeffrey K.

PY - 2011/7/1

Y1 - 2011/7/1

N2 - One branch of the tryptophan catabolic cascade is the kynurenine pathway, which produces neurotoxic [3-hydroxykynurenine (3-OHKY), quinolinic acid] and neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts as a competitive antagonist at the glycine site of N-methyl-d-asparate receptors at high concentrations and as a non-competitive antagonist on the α7- nicotinic acetylcholine receptor at low concentrations. Kynurenine compounds also influence cognitive functions known to be disrupted in schizophrenia. Alterations in tryptophan metabolism are therefore of potential significance for the pathophysiology of this disorder. In this paper, tryptophan metabolites were measured from plasma using high-pressure liquid chromatography coupled with electrochemical coulometric array detection, and relationships were tested between these metabolic signatures and clinical symptoms for 25 first-episode neuroleptic-naive schizophrenia patients. Blood samples were collected and clinical and neurological symptoms were rated at baseline and again at 4 wk following initiation of treatment. Level of 3-OHKY and total clinical symptom scores were correlated when patients were unmedicated and neuroleptic-naive, and this relationship differed significantly from the correlation observed for patients 4 wk after beginning treatment. Baseline psychosis symptoms were predicted only by neurological symptoms. Moreover, baseline 3-OHKY predicted clinical change at 4 wk, with the lowest concentrations of 3-OHKY being associated with the greatest improvement in symptoms. Taken together, our findings suggest a neurotoxic product of tryptophan metabolism, 3-OHKY, predicts severity of clinical symptoms during the early phase of illness and before exposure to antipsychotic drugs. Baseline level of 3-OHKY may also predict the degree of clinical improvement following brief treatment with antipsychotics.

AB - One branch of the tryptophan catabolic cascade is the kynurenine pathway, which produces neurotoxic [3-hydroxykynurenine (3-OHKY), quinolinic acid] and neuroinhibitory (kynurenic acid) compounds. Kynurenic acid acts as a competitive antagonist at the glycine site of N-methyl-d-asparate receptors at high concentrations and as a non-competitive antagonist on the α7- nicotinic acetylcholine receptor at low concentrations. Kynurenine compounds also influence cognitive functions known to be disrupted in schizophrenia. Alterations in tryptophan metabolism are therefore of potential significance for the pathophysiology of this disorder. In this paper, tryptophan metabolites were measured from plasma using high-pressure liquid chromatography coupled with electrochemical coulometric array detection, and relationships were tested between these metabolic signatures and clinical symptoms for 25 first-episode neuroleptic-naive schizophrenia patients. Blood samples were collected and clinical and neurological symptoms were rated at baseline and again at 4 wk following initiation of treatment. Level of 3-OHKY and total clinical symptom scores were correlated when patients were unmedicated and neuroleptic-naive, and this relationship differed significantly from the correlation observed for patients 4 wk after beginning treatment. Baseline psychosis symptoms were predicted only by neurological symptoms. Moreover, baseline 3-OHKY predicted clinical change at 4 wk, with the lowest concentrations of 3-OHKY being associated with the greatest improvement in symptoms. Taken together, our findings suggest a neurotoxic product of tryptophan metabolism, 3-OHKY, predicts severity of clinical symptoms during the early phase of illness and before exposure to antipsychotic drugs. Baseline level of 3-OHKY may also predict the degree of clinical improvement following brief treatment with antipsychotics.

KW - 3-hydroxykynurenine

KW - Cognition

KW - first-episode psychosis

KW - neuroleptic-naive

KW - neurological symptoms

KW - schizophrenia

KW - tryptophan

UR - http://www.scopus.com/inward/record.url?scp=79958813560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958813560&partnerID=8YFLogxK

U2 - 10.1017/S1461145710001689

DO - 10.1017/S1461145710001689

M3 - Article

C2 - 21275080

AN - SCOPUS:79958813560

VL - 14

SP - 756

EP - 767

JO - International Journal of Neuropsychopharmacology

JF - International Journal of Neuropsychopharmacology

SN - 1461-1457

IS - 6

ER -